Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer

April 21, 2016

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells. The programmed death 1 (PD-1) pathway dampens immune responses to tumor cells, and several clinical trials have shown favorable outcomes by targeting PD-1 or its ligand PD-1L.

In this issue of JCI Insight, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology examined PD-1-expressing regulatory T cells in glioblastoma multiforme, an extremely aggressive form of brain cancer. Regulatory T cells normally constrain immune responses and keep other types of T cells from mounting hyper-aggressive responses.

Although anti-PD1 therapy is generally thought to promote conventional T cell activity, the Hafler team now reports that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.

They also found that glioblastoma multiforme patients treated with a PD-1 blocking antibody had a higher proportion of dysfunctional regulatory T cells. These observations suggest the possibility that PD-1 targeting therapies could work, in part, by driving further regulatory T .

Future studies will be needed to more fully understand the contribution of this pathway to anti-tumor effects.

Explore further: Histone deacetylase inhibitors enhance immunotherapy in lung cancer models, researchers say

More information: Daniel E. Lowther et al, PD-1 marks dysfunctional regulatory T cells in malignant gliomas, JCI Insight (2016). DOI: 10.1172/jci.insight.85935

Related Stories

Overcoming immune exhaustion from chronic HIV infection

December 3, 2015

Chronic HIV infection results in exhaustion of the immune system, a phenomenon characterized by dysfunctional HIV-specific killer T cells. The exhausted T cells display inhibitory proteins on their surface, and scientists ...

Innate immune landscape in glioblastoma patient tumors

February 25, 2016

Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.